Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Conditions
Non-Small-Cell Lung Cancer · Metastatic Non-Small-Cell Lung Cancer · Advanced Non-Small-Cell Lung Cancer · EGFR P-Loop and Alpha C-Helix Compressing · EGFR PACC · EGFR Uncommon Mutations
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
UCSF Medical Center-Mission Bay, San Francisco, California, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
University of Colorado Health, Aurora, Colorado, United States
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
University of Illinois Hospital and Health Sciences Systems, Chicago, Illinois, United States
Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success, New York, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Ohio State University Hospitals, Columbus, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Texas Oncology, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Shenandoah Oncology, P.C., Winchester, Virginia, United States
Swedish Cancer Institute, Edmonds, Washington, United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
GenesisCare North Shore Health Hub, St Leonards, New South Wales, Australia
Austin Health, Heidelberg, Victoria, Australia
Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada
BC Cancer Vancouver Centre, Vancouver, British Columbia, Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Sunnybrook Research Institute, Toronto, Ontario, Canada
Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada
Hospices Civil de Lyon, Bron, Auvergne-Rhône-Alpes, France
Hospital Nord de Marseille, Marseille, Bouches-du-Rhone, France
Centre Francois Baclesse, Caen, Calvados, France
Hopital Larrey, Toulouse, Occitanie, France
Centre Leon-Berard, Lyon, France
Hopital Nord Guilaume-et-Rene-Laennec CHU de Nantes, Saint-Herblain, France
Insitut de Canderologie d I'Ouest, Saint-Herblain, France
Henry Dunant Hospital Center, Athens, Greece
University General Hospital Attikon - General Hospital of West Attica H AGIA VARVARA, Athens, Greece
Athens Medical Center S.A., European Interbalkan Medical Center, Thessaloniki, Greece
Thoracic General Hospital of Athens I Sotiria, Thessaloniki, Greece
Queen Mary Hospital, Hong Kong, Hong Kong, Hong Kong
Humanity and Health Clinical Trial Centre, Central, Hong Kong
SOC Oncologia Medica e dei Tumori Immuno-correlati, Aviano, Italy
Istituto Europeo di Oncologia (IEO), Milan, Italy
Aichi Cancer Center, Nagoya, Aichi-ken, Japan
Kurume University Hospital, Kurume-Shi, Fukuoka, Japan
National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
Hyogo Cancer Center, Akashi-shi, Hyōgo, Japan
Miyagi Cancer Center, Natori-shi, Miyagi, Japan
Niigata Cancer Center Hospital, Niigata, Niigata, Japan
Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Tokyo, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
OncoCar Cancer Centre, Petaling Jaya, Selangor, Malaysia
Hospital Kuala Lumpur, Kuala Lumpur, WP Kuala Lumpur, Malaysia
National Cancer Centre Singapore, Singapore, Singapore
Curie Oncology (Farrer), Singapore, Singapore
Tan Tok Seng Hospital, Singapore, Singapore
The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, South Korea
Gachon University Gil Medical Center, Incheon, South Korea
Kyung Hee University Hospital, Seoul, South Korea
Kangbuk Samsung Hospital, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Hospital Universitari Son Espases, Palma, Balearic Islands, Spain
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital QuironSalud Malaga, Málaga, Spain
Hospital Universitario Central de Asturias, Oviedo, Spain
Hospital Universitario y Politecnico La Fe, Valencia, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Taichung Veterans General Hospital, Taichung, Taiwan
National Taiwan University Cancer Center, Taipei, Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan
Mahidol University - Siriraj Hospital, Bangkoknoi, Bangkok, Thailand
Chulabhorn Hospital, Lak Si, Bangkok, Thailand
Prince of Songkla Hospital, Hat Yai, Changwat Songkhla, Thailand
University College London Hospitals NHS Foundation Trust, London, England, United Kingdom
The Christie NHS Foundation Trust, Manchester, England, United Kingdom
The Royal Marsden NHS Foundation Trust, London, United Kingdom
Study leads
Morgan Lam
Study Director
ArriVent BioPharm